Modern diagnostic and management aspects of citrate therapy for uric acid nephrolithiasis


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Introduction. Iso-aciduria - long-term existence of urine pH within a narrow range (pH <0.8-1.2 units.) - activates certain enzymes for which these pH levels are favorable. Then, this activation induces precipitation of crystals corresponding to these enzymes. Objective. To enable citrate therapy without a risk of altering the stone chemical composition and to identify indicators reflecting the degree of metabolic disorders in patients with uric acid nephrolithiasis. Material and methods. Citrate therapy was provided with a mixture comprising «Potassium citrate monohydrate» and «Tri-sodium citrate di-hydrate» in a ratio of 2: 1. The study group included 64 patients, who had ultrasound-detected calyx stones and hyperechoic inclusions from 2 to 4 mm without acoustic shadow, located in the papillary region of the renal pyramids. Statistical analysis was performed by cross tabulations (pairing). Results. The results of the statistical analysis have proven the legitimacy and feasibility of the proposed method of classifying patients into homogeneous groups according to the disease severity. Conclusion. Long-term citrate therapy should be carried out in such a way as to achieve maximum range of urine pH (from 5.4 to 7.8 units), which will allow to avoid deposition of other crystals upon the existing stone and identify indicators reflecting the degree of metabolic disorders in patients with uric acid nephrolithiasis. Conclusion. Long-term citrate therapy should be carried out in such a way as to achieve maximum range of urine pH (from 5.4 to 7.8 units), thus avoiding deposition of other crystals upon the existing stone.

Full Text

Restricted Access

About the authors

S. N Alekseenko

Kuban’ State Medical University

Department of Urology

A. S Tatevosyan

Kuban’ State Medical University

Email: artur-krasnodar@bk.ru
Department of Urology

V. L Medvedev

Kuban’ State Medical University

Department of Urology

A. G Tonyan

Kuban’ State Medical University

Email: tonyanag@rambler.ru
Urologist at the Multidisciplinary Medical Center LLC «City Clinic», PhD

S. S. Ryabokon'

Kuban’ State Medical University

Department of Urology

References

  1. Аполихин О.И., Сивков А.В., Бешлиев ДА Анализ урологической заболеваемости в Российской Федерации в 2002-2009 гг. по данным официальной статистики. Экспериментальная и клиническая урология. 2011;1:4-10
  2. Урология национальное руководство. М.: ГЭОТАР-Медиа. 2009.1024 с
  3. Кадыров З.А., Истратов В.Г., Сулейманов С.И. Мочекаменная болезнь. М., Бином. 2013. 184 с
  4. Capasso G., Jaeger P., Robertson W. Uric acid and the kidney: urate transport? Stone disease and progressive renal failure. Curr Pharm Des. 2005;11(32):4153-59.
  5. Александров В.П. Скрябин Г. Мочекислый уролитиаз. Методические рекомендации. СПб., 1993. 26 с.
  6. Татевосян А.С. Этиологические и патогенетические основы нефролитиаза. Краснодар, «Советская Кубань». 1997. 150 с.
  7. Аляев Ю.Г., Кузьмичева Г.М., Руденко В.И. Современные аспекты цитратной терапии у больных мочекаменной болезнью. Врачебное сословие. 2004;4:20-24
  8. Колпаков И.С. Мочекаменная болезнь. М., Академия. 2006. 222 с.
  9. Левковский С.Н. Мочекаменная болезнь: прогнозирование течения и метафилактика. СПб., Береста. 2010. 118 с.
  10. Колпаков И.С. Консервативное лечение мочекаменной болезни. М., МИА. 2009.148 с.
  11. Глыбочко П.В., Аляев Ю.Г., Рапопорт Л.М. Современная консервативная (цитратная) терапия при уратных камнях мочеточников. Урология. 2014;5:10-18
  12. Xu H., Zisman A.L., Coe F.L., Worcester E.M. Kidney stones: an update on current pharmacological management and future directions. Expert Opin Pharmacoter. 2013;14(4):435-447.
  13. Татевосян А.С. Способ консервативного лечения мочекаменной болезни и предупреждения рецидивного образования камней почек. Патент на изобретение № 2253366. Зарегистрировано в Гос. реестре изобретений РФ 2005 г.
  14. Алексеенко С.Н., Медведев В.Л., Татевосян А.С. Способ определения степени тяжести течения мочекислого уролитиаза. Патент на изобретение № 2517221. Зарегистрировано в Гос. реестре изобретений РФ 2014 г.

Supplementary files

Supplementary Files
Action
1. JATS XML

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies